Skip to main content

IOANNIS GRIVEAS

MD,PhD

Presentations

  • 137. Pneumonia due to nocardia in a patient with minimal change and nephrotic syndrome.
    Ι. Griveas, A. Balitsari, N. Tzimas, et al.
    417 NIMTS
    90th meeting Hellenic Renal Society, Thessaloniki November 2015.
  • 138. Correlation of abdominal aortic calcification with cardiac hypertrophy, pulse pressure and mineral and bone disease biochemistries in hemodilaysis patients.
    D. Bacharaki, I. Griveas, K. Stamatelou, P. Sitaras.
    52nd ERA-EDTA, London 28-31 May 2015 British Renal Society Annual Conference, 30th Hune-2nd July 2015, Leeds, UK.
  • 139. Soluble Urokinase Plasminogen Receptor (SUPAR): A future risk marker for hemodialysis patients?
    I. Griveas, C. Andriopoulos, P. Sitaras, M. Aktsiali.
    52nd ERA-EDTA, London 28-31 May 2015 and British Renal Society Annual Conference, 30th Hune-2nd July 2015, Leeds, UK.
  • 140. CLINICAL EXPERIENCE WITH ORAL SUCROSOMIAL IRON IN A SEVERE ANEMIC PATIENT WITH CHRONIC KIDNEY DISEASE.
    I. Griveas
    4th Mediterranean Multidisciplinary Course on Iron Anemia April 29th–30th 2016, Madrid, Spain.
  • 141. EFFECT OF ORAL ORAL SUCROSOMIAL IRON IN CKD PATIENTS WITH ANEMIA.
    I. Griveas
    4th Mediterranean Multidisciplinary Course on Iron Anemia April 29th–30th 2016, Madrid, Spain.
  • 142. Εffect of citrate based on anticoagulation therapy in maintenance haemodialysis patients.
    I. Griveas.
    19th Hellenic Nephrology Conference, Kalamata 11-14 May 2016 and 53rd ERA-EDTA, Vienna 21-24 May 2016.
  • 143. Correlation left ventricle mass and Vascular calcification in hemodialysis patients
    D. Baharaki, K. Stamatellou, I. Griveas, et al.
    19th Hellenic Nephrology Conference, Kalamata 11-14 May 2016.
  • 144. Vascular calcification of abdominal aorta as prognostic factor of mortality in hemodialysis patients.
    D. Baharaki, K. Stamatellou, I. Griveas, et al.
    19th Hellenic Nephrology Conference, Kalamata 11-14 May 2016.
  • 145. Abdominal Aortic Calicifications as a Prognostic Factor of All Cause Mortality in Hemodialysis Patients
    Kyriaki Stamatelou,1 Dimitra Bacharaki,2 Ioannis Griveas,3 John Kyriazis,4 Dimitrios V. Vlahakos.2 1Nephrology, Galinos
    Hospital, Athens, Greece; 2Nephrology, Atticon Hospital, Chaidari, Greece; 3Dialysis, NEFROIATRIKI, Athens, Greece; 4Nephrology, General Hospital, Chios, Greece.
    ASN-Renal week , Chicago 15-20 November 2016.
  • 146. Efficacy And Safety Of Sucroferric Oxyhydroxide In Haemodialysis Patients With Mineral Bone Disease
    Ioannis Griveas1,2, Panagiotis Sitaras2, Christos Andriopoulos3, Maro Aktsiali4
    1417 NIMTS, Nephrology Department, Chalandri, Athens, GREECE, 2Private Dialysis Unit, Dialysis Unit, Metamorphosi, Athens, GREECE, 3Private Dialysis Unit "Nefroiatriki", Nephrology, Metamorphosi, Athens, GREECE, 4Private Dialysis Unit "Nefroiatriki", Dialysis Unit, Metamorphosi, Athens, GREECE.
    Session Info: Poster Session: Dialysis - Bone disease
    I.Griveas, C. Andriopoulos, P. Sitaras, M. Aktsiali.
    1Private Dialysis Unit “Nefroiatriki”, Athens, Greece; 2 Nephrology, 417 Veterans Army Administration Hospital of Athens, Athens, Greece.2 Renal Clinic “Athens - Nephrology”, Athens, Greece.
    Group/Team: Private Dialysis Unit "NEFROIATRIKI".
    54th ERA-EDTA, Madrid 3-6 June 2017.
  • 147. HCV Viraemia in Anti-HCV-Negative Haemodialysis Patients: A Myth?
    Ioannis Griveas.1,2
    1 401 General Military Hospital of Athens, Athens, Greece; 2Private Dialysis Unit “Nefroiatriki”, Athens, Greece.
    ASN-Renal week , N. Orleans 31 October-20 November 2017
  • 148. Impact of Oral Sucrosomial Iron in Anemia of CKD Patients and Its Relation with Mineral Bone Disease Parameters
    Ioannis Griveas.1,2
    1 401 General Military Hospital of Athens, Athens, Greece; 2Renal Clinic “Athens - Nephrology”, Athens, Greece.
    ASN-Renal week , N. Orleans 31 October-20 November 2017
  • 149. Sucroferric Oxyhydroxide: A Novel Phosphate Binder Only or Something More?
    I.Griveas. 1, 2
    Private Dialysis Unit “Nefroiatriki”, Athens, Greece; 2 Nephrology, 417 Veterans Army Administration Hospital of Athens, Athens, Greece. 2 Renal Clinic “Athens - Nephrology”, Athens, Greece.
    Group/Team: Private Dialysis Unit "NEFROIATRIKI".
    ASN-Renal week , N. Orleans 31 October-20 November 2017
  • 150. Sucroferric Oxyhydroxide: A Novel Phosphate Binder For The Management Of Mineral Bone Disease In Dialysis Patients With "Pleiotropic" Effects
    I.Griveas, C. Andriopoulos, P. Sitaras, M. Aktsiali.
    1Private Dialysis Unit “Nefroiatriki”, Athens, Greece; 2 Nephrology, 417 Veterans Army Administration Hospital of Athens, Athens, Greece. 2 Renal Clinic “Athens - Nephrology”, Athens, Greece.
    Group/Team: Private Dialysis Unit "NEFROIATRIKI".
    55th ERA-EDTA, Copenhagen 24-27 May 2018.
  • 151. The Efficacy of Ascorbate - Rich Dialysate to attenuate Anaemia in maintenance Hemodialysis Patients
    Ioannis Griveas.1,2
    1 Private Dialysis Unit “Nefroiatriki”, Athens, Greece; 2 Nephrology, 417 Veterans Army Administration Hospital of Athens, Athens, Greece.
    2 Renal Clinic
    55th ERA-EDTA, Copenhagen 24-27 May 2018. And XIX International Congress On Nutrition And Metabolism In Renal Disease (ICRNM 2018) Genova, Italy - June 26/30, 2018
    “Athens-Nephrology”, Athens, Greece.
    Group/Team: Private Dialysis Unit "Nefroiatriki".